InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,426.40
(
0.12%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.80
(
0.01%
)
Bitcoin
65,277.11
(
0.21%
)
Post# of 252254
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119875
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 156480

Tuesday, 02/05/2013 1:42:51 PM

Tuesday, February 05, 2013 1:42:51 PM

Post# of 252254
I’m not as cynical as oc631, so I don’t think GILD is seeking to profit by treating many genotype-3 patients twice rather than once.

If extending Sofosbuvir + ribavirin from 12w to 16w does not make a significant improvement in the FUSION study, I think GILD will look to add a third drug—not necessarily GS-5885—for genotype-3.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up